Saccharomyces cerevisiae for irritable bowel syndrome

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 11 Sep 2025: Trial registered, NCT07168434
  2. 22 Oct 2025: Trial started, NCT07168434

The trials

NCT07168434: Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome

State
Under way
Phase
Phase 3
People
406 planned
Started
22 Oct 2025
Primary completion
11 Oct 2026
Arms
Treatment
Results
None posted
  1. 11 Sep 2025: Trial registered
  2. 22 Oct 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as S. boulardii CNCM (National Collection of Cultures of Microorganisms) I-745, Saccharomyces Boulardii 250 MG.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.